Search Results - "Filetti M"

3190eP Prognostic value of unplanned hospital attendances in early phase cancer trial participants.

Authors: Lombardi, P. Filetti, M. Cortellini, A. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS694-S695. 2p.

Latency as a region contrast: Measuring ERP latency differences with Dynamic Time Warping.

Authors: Zoumpoulaki, A. Alsufyani, A. Filetti, M. et al.

Source: Psychophysiology. Dec2015, Vol. 52 Issue 12, p1559-1576. 18p. 2 Black and White Photographs, 9 Charts, 11 Graphs.

Subjects: Evoked potentials (Electrophysiology), Cognitive psychology, Computer simulation, Signal-to-noise ratio, Time series analysis, Electroencephalography

2322P Editorial oversight of AI in high-impact oncology journals: A cross-sectional policy analysis.

Authors: Filetti, M. Lombardi, P. Moro, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1274-S1274. 1p.

1585P Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023).

Authors: Iannantuono, G.M. Filetti, M. Giudice, E. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS956-S957. 2p.

133P ARID1A-mutated cancers: New prospectives for treatment of a subgroup of gynecological cancer.

Authors: Falcone, R. Filetti, M. Lombardi, P. et al.

Source: Annals of Oncology. 2022 Supplement 8, Vol. 33, pS1425-S1425. 1p.

1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis.

Authors: Filetti, M. Lombardi, P. Falcone, R. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1266-S1266. 1p.

1081P DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients.

Authors: Filetti, M. Occhipinti, M. Cirillo, A. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1047-S1047. 1p.

10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status.

Authors: Cortellini, A. Filetti, M. Citarella, F. et al.

Source: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1378-S1378. 1p.

8P Clinical trial design in the era of precision oncology: An overview of the last 20 years.

Authors: Filetti, M. Lombardi, P. Falcone, R. et al.

Source: Annals of Oncology. 2021 Supplement 6, Vol. 32, pS1348-S1348. 1p.

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.

Authors: Mazzotta, M. Filetti, M. Rossi, A. et al.

Source: Annals of Oncology. Mar2020, Vol. 31 Issue 3, p440-441. 2p.

79P Statins and immunotherapy: Togetherness makes strength - the potential effect of statins on immunotherapy for NSCLC.

Authors: Filetti, M. Rossi, A. Piras, M. et al.

Source: Annals of Oncology. 2020 Supplement 7, Vol. 31, pS1449-S1449. 1p.

ERP latency contrasts using Dynamic Time Warping algorithm.

Authors: Zoumpoulaki, A. Alsufyani, A. Filetti, M. et al.

Source: BMC Neuroscience. 2013, Vol. 14 Issue Suppl 1, p1-2. 2p.

2191P Global gaps in bereavement education and associated emotional morbidity among oncology residents: Findings from a 21 country cross-sectional survey.

Authors: Giusti, R. Loupakis, F. Moro, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1222-S1222. 1p.

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.

Authors: Marinelli, D. Mazzotta, M. Scalera, S. et al.

Source: Annals of Oncology. Dec2020, Vol. 31 Issue 12, p1746-1754. 9p.

1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC).

Authors: Citarella, F. Russano, M. Fiorenti, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS848-S848. 1p.

1845P Features of clinical trials leading to oncologic drugs approval in europe.

Authors: Duranti, S. Lombardi, P. Falcone, R. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS1244-S1245. 2p.

LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study.

Authors: Bersanelli, M. Giannarelli, D. Verzoni, E. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1209-S1209. 1p.

Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journals.

Authors: Giusti R Filetti M Lombardi P et al.

Source: Frontiers in oncology [Front Oncol] 2026 Apr 01; Vol. 16, pp. 1717048. Date of Electronic Publication: 2026 Apr 01 (Print Publication: 2026).

Publication Type: Journal Article; Systematic Review

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Current landscape of T-cell engagers in early-phase clinical development in solid cancers.

Authors: Spinazzola A Iannantuono GM Gulley JL et al.

Source: Frontiers in immunology [Front Immunol] 2025 Oct 06; Vol. 16, pp. 1665838. Date of Electronic Publication: 2025 Oct 06 (Print Publication: 2025).

Publication Type: Journal Article; Review

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

The financial toll of cancer: uncovering the links between financial toxicity and symptom burden.

Authors: Filetti M Lombardi P Gentile G et al.

Source: The oncologist [Oncologist] 2025 Jun 04; Vol. 30 (6).

Publication Type: Journal Article; Multicenter Study; Observational Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE